Logo image of BIAF

BIOAFFINITY TECHNOLOGIES INC (BIAF) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BIAF - US09076W3079 - Common Stock

1.48 USD
-0.03 (-1.99%)
Last: 12/15/2025, 6:34:11 PM
1.5286 USD
+0.05 (+3.28%)
After Hours: 12/15/2025, 6:34:11 PM
Fundamental Rating

2

Taking everything into account, BIAF scores 2 out of 10 in our fundamental rating. BIAF was compared to 529 industry peers in the Biotechnology industry. Both the profitability and financial health of BIAF have multiple concerns. BIAF does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BIAF had negative earnings in the past year.
In the past year BIAF has reported a negative cash flow from operations.
In the past 5 years BIAF always reported negative net income.
In the past 5 years BIAF always reported negative operating cash flow.
BIAF Yearly Net Income VS EBIT VS OCF VS FCFBIAF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

With a Return On Assets value of -127.65%, BIAF is not doing good in the industry: 82.23% of the companies in the same industry are doing better.
With a Return On Equity value of -165.57%, BIAF is not doing good in the industry: 66.92% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -127.65%
ROE -165.57%
ROIC N/A
ROA(3y)-100.74%
ROA(5y)-1117.09%
ROE(3y)-194.9%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BIAF Yearly ROA, ROE, ROICBIAF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

1.3 Margins

The Gross Margin of BIAF (27.86%) is better than 72.59% of its industry peers.
The Profit Margin and Operating Margin are not available for BIAF so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 27.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIAF Yearly Profit, Operating, Gross MarginsBIAF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

3

2. Health

2.1 Basic Checks

BIAF does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BIAF has more shares outstanding
Compared to 1 year ago, BIAF has a worse debt to assets ratio.
BIAF Yearly Shares OutstandingBIAF Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 100K 200K 300K 400K 500K
BIAF Yearly Total Debt VS Total AssetsBIAF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -8.12, we must say that BIAF is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -8.12, BIAF is doing worse than 69.94% of the companies in the same industry.
BIAF has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
BIAF has a Debt to Equity ratio (0.01) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -8.12
ROIC/WACCN/A
WACC8.02%
BIAF Yearly LT Debt VS Equity VS FCFBIAF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

A Current Ratio of 3.65 indicates that BIAF has no problem at all paying its short term obligations.
The Current ratio of BIAF (3.65) is comparable to the rest of the industry.
BIAF has a Quick Ratio of 3.64. This indicates that BIAF is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.64, BIAF is in line with its industry, outperforming 45.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.65
Quick Ratio 3.64
BIAF Yearly Current Assets VS Current LiabilitesBIAF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

BIAF shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.38%, which is quite good.
BIAF shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -27.66%.
EPS 1Y (TTM)13.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.25%
Revenue 1Y (TTM)-27.66%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-38.47%

3.2 Future

Based on estimates for the next years, BIAF will show a very strong growth in Earnings Per Share. The EPS will grow by 29.26% on average per year.
The Revenue is expected to decrease by -12.63% on average over the next years. This is quite bad
EPS Next Y41.46%
EPS Next 2Y29.26%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-36.4%
Revenue Next 2Y-12.63%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

BIAF Yearly Revenue VS EstimatesBIAF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2M 4M 6M 8M
BIAF Yearly EPS VS EstimatesBIAF Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BIAF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BIAF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIAF Price Earnings VS Forward Price EarningsBIAF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIAF Per share dataBIAF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

BIAF's earnings are expected to grow with 29.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.26%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BIAF does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

BIOAFFINITY TECHNOLOGIES INC

NASDAQ:BIAF (12/15/2025, 6:34:11 PM)

After market: 1.5286 +0.05 (+3.28%)

1.48

-0.03 (-1.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/bmo
Earnings (Next)03-30 2026-03-30
Inst Owners8.78%
Inst Owner Change-19.84%
Ins Owners2.77%
Ins Owner Change0%
Market Cap6.66M
Revenue(TTM)6.78M
Net Income(TTM)-14.74M
Analysts43.33
Price TargetN/A
Short Float %2.61%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-69.39%
Min EPS beat(2)-72.11%
Max EPS beat(2)-66.67%
EPS beat(4)1
Avg EPS beat(4)-45.97%
Min EPS beat(4)-72.11%
Max EPS beat(4)1.96%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-8.45%
Min Revenue beat(2)-17.38%
Max Revenue beat(2)0.49%
Revenue beat(4)1
Avg Revenue beat(4)-10.3%
Min Revenue beat(4)-17.38%
Max Revenue beat(4)0.49%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2900%
EPS NY rev (1m)0%
EPS NY rev (3m)-3500%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.98
P/FCF N/A
P/OCF N/A
P/B 0.75
P/tB 0.98
EV/EBITDA N/A
EPS(TTM)-20.94
EYN/A
EPS(NY)-8.26
Fwd EYN/A
FCF(TTM)-1.89
FCFYN/A
OCF(TTM)-1.88
OCFYN/A
SpS1.51
BVpS1.98
TBVpS1.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -127.65%
ROE -165.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 27.86%
FCFM N/A
ROA(3y)-100.74%
ROA(5y)-1117.09%
ROE(3y)-194.9%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.33%
Cap/Sales 0.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.65
Quick Ratio 3.64
Altman-Z -8.12
F-Score4
WACC8.02%
ROIC/WACCN/A
Cap/Depr(3y)740.75%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.25%
EPS Next Y41.46%
EPS Next 2Y29.26%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-27.66%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-38.47%
Revenue Next Year-36.4%
Revenue Next 2Y-12.63%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-24.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-42.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-47.67%
OCF growth 3YN/A
OCF growth 5YN/A

BIOAFFINITY TECHNOLOGIES INC / BIAF FAQ

Can you provide the ChartMill fundamental rating for BIOAFFINITY TECHNOLOGIES INC?

ChartMill assigns a fundamental rating of 2 / 10 to BIAF.


What is the valuation status of BIOAFFINITY TECHNOLOGIES INC (BIAF) stock?

ChartMill assigns a valuation rating of 1 / 10 to BIOAFFINITY TECHNOLOGIES INC (BIAF). This can be considered as Overvalued.


Can you provide the profitability details for BIOAFFINITY TECHNOLOGIES INC?

BIOAFFINITY TECHNOLOGIES INC (BIAF) has a profitability rating of 1 / 10.


How financially healthy is BIOAFFINITY TECHNOLOGIES INC?

The financial health rating of BIOAFFINITY TECHNOLOGIES INC (BIAF) is 3 / 10.